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Abstract
Despite the major advances in medical drug therapy, heart failure remains a syndrome
associated with high mortality and morbidity. Biventricular or left ventricular (LV) short
atrioventricular (AV) delay pacing is being tested in congestive heart failure patients with left
bundle branch block. The aim is to resynchronise the dyscoordinate LV contraction. A
number of studies are underway, but it is clear that while some patients respond remarkably,
this is highly variable. Accurate identification of patients likely to benefit will be crucial. The
mechanism of benefit is unclear. A greater understanding of the physiological consequences
of pacing will be necessary to accurately identify these patients.
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Introduction
During the past two decades there have been major
advances in the pharmacological treatment of chronic
heart failure. Despite this, severe heart failure remains a
syndrome associated with very high mortality, profound
reduction in quality of life, and frequent hospitalisation.
Cardiac transplantation can be an extremely effective
therapy in such cases, but its provision is severely rationed
by the lack of available donor organs. This rationing will
remain unless xenotransplantation becomes a reality.
Other cardiac surgical interventions including revasculari-
sation, dynamic cardiomyoplasty and myocardial reduction
surgery have been employed, but are currently of
unproven value. It is in this context that pacemaker therapy
is currently being intensively evaluated as a therapy for
such patients.
Short atrioventricular delay right-sided pacing
Initial interest in the role of pacing as a potential treatment
for congestive heart failure (CHF) focused on prolonging
diastolic filling time by reducing or abolishing presystolic
AV valve regurgitation.
Rutishauser et al first reported the phenomenon of presys-
tolic AV valve regurgitation in patients with CHF and com-
plete heart block [1]. It became apparent with the advent
of Doppler echocardiography that such presystolic regur-
gitation of the mitral and/or tricuspid valves is common in
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patients with first-degree AV or complete heart block
[2–4]. Presystolic regurgitation has also been reported in
CHF patients with normal AV conduction times if left ven-
tricular end diastolic pressure (LVEDP) is markedly
increased [5,6]. The AV pressure gradient, when LVEDP
is high and the conduction time is prolonged, is thought to
reverse before the onset of ventricular systole. Although
this promotes valve closure, there is incomplete closure,
resulting in valvular regurgitation and reduced ventricular
filling time. In the context of a ventricle that is abnormally
stiff (and therefore highly dependent on filling time, espe-
cially on exercise), this can have considerable adverse
haemodynamic consequences. The presence of interven-
tricular conduction prolongation (wide QRS complex)
further shortens the left ventricular filling period [7].
Hochleitner et al first reported beneficial effects from dual-
chamber short AV delay (100 ms) pacing in patients on a
transplantation waiting list, but did not establish the mech-
anism of benefit [8]. Brecker et al subsequently reported
improved exercise capacity and haemodynamics in 12
CHF patients with short AV delay pacing. Pacing with a
short AV interval eliminated the presystolic component of
AV valve regurgitation and increased ventricular diastolic
filling times [5]. These observations were supported by
smaller uncontrolled studies [9,10]. Since then, further
reports of unselected patients have shown no overall
short- or medium-term benefits; while individual patients
have improved, others have deteriorated [11–13].
These mixed results may be explained by the fact that bene-
fits from the reduction in presystolic AV valve regurgitation
may be offset by the electromechanical dyssynchrony of
right ventricular (RV) pacing. Right-sided pacing results in
paradoxical motion of the interventricular septum (as seen in
left bundle branch block [LBBB]). This may adversely affect
LV performance as it may reduce LV diastolic filling time,
result in dyssynchronous (and inefficient) LV contraction
and reverse the normal base–apex activation sequence.
In a study of patients with coronary heart disease but
without CHF, Betocchi et al demonstrated that right-sided
AV sequential pacing caused an upward shift in the LV
diastolic pressure–volume relation. There was also a
reduction in LV peak filling rate, an increase in the time
constant of isovolumic relaxation (tau), and a reduction in
cardiac index [14]. Rosenqvist et al used radionuclide ven-
triculography to assess exercise responses in 12 patients
without CHF. Cardiac output measured on exercise (with
similar heart rates) was higher during atria pacing than
during either dual chamber pacing or ventricular pacing.
Paradoxical septal motion was apparent during ventricular
pacing and dual chamber pacing, with a 25% impairment
of regional septal ejection fraction [15]. There is, therefore,
clear evidence that RV pacing impairs both systolic and
diastolic function of the LV in patients without CHF.
Attempts to normalise the base–apex electromechanical
sequence have produced conflicting results. Several
studies in normal dogs and in patients without CHF have
suggested that pacing from the RV outflow tract or inter-
ventricular septum may be superior to RV apical pacing
[16–19]. Both acute haemodynamic and long-term
studies in patients with CHF, however, have not shown
any benefit [13,20,21].
Further evidence against RV pacing for CHF comes from
the observation that it results in an increase in plasma nor-
epinephrine levels [22] (a powerful adverse prognostic
marker in CHF [23]).
The response to right-sided AV sequential pacing in CHF
may depend on a balance between beneficial alleviation of
presystolic mitral regurgitation (MR) and tricuspid regurgi-
tation (TR) (in those patients with AV conduction delay
and elevated LVEDP), and adverse consequences of dys-
synchrony of left ventricular contraction and filling. Consis-
tent with this, Nishimura et al reported that benefit was
confined to those patients with presystolic MR and pro-
longed AV conduction, whereas other patients showed a
worsening of haemodynamics [10]. It has been sug-
gested, on this basis, that the decision to implant such a
pacemaker should be based on the haemodynamic
response to an acute pacing study [24]. However, enthu-
siasm for right-sided short AV delay pacing as a treatment
for CHF has waned.
Biventricular and left ventricular pacing
In much the same way that RV pacing induces LV dys-
function, a similar dysfunction may arise from LBBB in
patients with CHF. This conduction abnormality is
present in 10–53% of patients with CHF and, when
present, is associated with a worse prognosis [25].
‘Resynchronisation’ of RV and LV contraction, by simul-
taneous (biventricular) pacing, would therefore appear
logical. The technical feasibility of such an approach was
reported by two groups in 1994 [26,27]; in these
reports, lead implantation was performed at thoraco-
tomy. Cazeau et al subsequently reported acute haemo-
dynamic benefit from temporary AV sequential
biventricular pacing in eight patients with severe CHF
[28]. Further support came from two larger acute studies
of patients with severe CHF. The first of these was from
Blanc et al, in which CHF patients with first-degree AV
block and/or LBBB, and a pulmonary capillary wedge
pressure >15 mmHg were paced with a short AV delay
and either biventricular, LV or RV pacing. Both LV and
biventricular configurations were haemodynamically
superior to baseline or to RV pacing [29]. Leclercq et al,
in a similar patient group, also observed an equal magni-
tude of benefit from LV and biventricular pacing, compar-
ing biventricular pacing with baseline or RV pacing (dual
chamber pacing) in this study [30].c
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The long-term results of the ‘Resynchronisation for Heart
Failure’ (In Sync) Trial were recently reported. This was an
open study of biventricular pacing in patients with med-
ically refractory NYHA III/IV heart failure with QRS dura-
tion >150 ms and left ventricular ejection fraction <35%.
The predetermined end points were 6 min walk distance,
NYHA functional class and quality of life at 1, 3, 6 and
12 months versus baseline. There were significant
improvements in all three parameters at each time point
when compared with baseline [31].
Several randomised and non-randomised studies of
biventricular pacing are currently in progress or planned.
Table 1 summarises the design (and where available
results) of studies that are either completed or due to
finish soon, whereas Table 2 lists the studies that have
yet to commence or are in the early phases. Most of
these studies are now assessing clinically important end
points such as exercise capacity and quality of life in
patients with severe CHF and LBBB. The Multisite Stim-
ulation in Cardiomyopathy (MUSTIC) study [32] is the
first single-blind, randomised, cross-over study of ventric-
ular resynchronisation therapy in CHF. The cross-over
design enabled patients to act as their own control,
being paced for 3 months in each mode (ie biventricu-
lar/no ventricular stimulation). The MUSTIC study con-
tained two patient groups: one in sinus rhythm and one in
atrial fibrillation post-atrioventricular nodal ablation. This
is based on the previous demonstration that, among
patients with CHF and poorly controlled atrial fibrillation,
AV nodal ablation and right ventricular pacing can result
in symptomatic improvement [33,34]. The inclusion crite-
ria for all patients were NYHA class III or IV, an ejection
fraction <35% and significant ventricular conduction
delay. The results of the sinus rhythm group have now
been reported [35–37]. Biventricular pacing significantly
improved both primary end points (VO2 max and 6 min
walk distance). There were significant improvements in
quality of life (Minnesota questionnaire) and also in
rehospitalisation (both prespecified secondary end
points). At the end of the cross-over phase, 86% of
patients chose (blind) biventricular pacing as their pre-
ferred mode for the longitudinal phase. Although further
studies will need to address the question of mortality
benefit, the availability of a non-pharmacological treat-
ment that improves exercise capacity and quality of life
would be a major advance. The quality-of-life issue is par-
ticularly pertinent as the baseline data in MUSTIC con-
firms the profound impairment of quality of life in NYHA
class III and IV heart failure. The only concern is that
some deaths occurred very soon after changes in pace-
maker programming (ie soon after the cross-over from
atria pacing to biventricular pacing or at the onset of
biventricular pacing), raising the possibility that patients’
biventricular pacing may be arrhythmogenic, perhaps
because of the presence of two ventricular activation
wave fronts. The timing of these few early deaths in a
small subset may be a chance finding but requires clarifi-
cation. One study has conversely shown a reduction in
ventricular ectopic activity by biventricular pacing [38].
Preliminary results from the acute and chronic phases of
the Pacing Therapies for Congestive Heart Failure (PATH-
CHF) study have also been reported recently. The acute
results emphasised the importance of optimising AV delay,
and showed that LV pacing was superior to both RV
pacing and biventricular pacing [39]. In the chronic study,
significant improvements in VO2 max, quality of life, 6
minute walk distance, NYHA class and ejection fraction
were observed, with a progressive increment of benefit
over the first 6 months. This benefit remained stable
between 6 and 12 months [40].
Results of VIGOR CHF will be reported shortly. Patients
with severe CHF due to dilated cardiomyopathy in sinus
rhythm with intraventricular conduction delay underwent
biventricular pacemaker insertion at thoracotomy. A
single-blind, cross-over phase of biventricular pacing or
no ventricular stimulation (6 weeks in each phase) fol-
lowed by a 12 week longitudinal paced phase is present.
The primary end point is the measurement of VO2 max.
Many patients with CHF meet the criteria for an
implantable cardioverter defibrillator (ICD) [41]. Patients
in VENTAK CHF with severe drug refractory CHF, a
QRS duration >120 ms and indications for ICD implan-
tation will undergo implantation of a biventricular pace-
maker/ICD. The study is otherwise similar to VIGOR
CHF [22]. The end points of the two studies are the
same except that antitachycardia and defibrillator effi-
cacy and safety are included as additional secondary
end points. The feasibility of combined trans-venous
biventricular pacing/automatic implantable cardioverter
defibrillator implantation has recently been reported [42],
leading to the addition of an ICD/pacing limb to the
MUSTIC study.
There are several studies in the ‘design and recruitment’
stage, some of which now address the issue of mortality
and healthcare cost issues; for example, Cardiac Resyn-
chronisation in Heart Failure (CARE-HF). This study aims
to assess mortality in a controlled patient group by ran-
domising patients to biventricular pacing and optimal
therapy, or optimal therapy alone. All-cause mortality and
hospital admissions for decompensated CHF will be eval-
uated together with an assessment of a 6 minute walk dis-
tance and VO2 max. The second end points of this study
will be NYHA status, mortality, quality of life, neurohor-
mone levels and echocardiographic indices.
Table 2 summarises the design of other important studies
planned or in the early phases, including PACMAN,
MIRACLE, COMPANION and RELEVANT.Current Controlled Trials in Cardiovascular Medicine    Vol 1 No 2 Morris-Thurgood and Frenneaux
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.The future
We are at a crucial point with this series of large clinical
trials in the adoption or otherwise of pacing for the treat-
ment of severe CHF.
Current philosophy on the use of pacing in CHF assumes
that the mechanism of benefit arises from resynchronisa-
tion of ventricular contraction in patients with LBBB. The
major studies are therefore evaluating biventricular pacing
in severe CHF associated with LBBB. The evidence in
support of this mechanism is far from conclusive.
If the mechanism of benefit was due to a resynchronisation
of both ventricles, then biventricular pacing (in which syn-
chronous depolarisation occurs together with a narrowing
of the QRS complex) would be expected to be superior to
LV pacing (which is associated with a much broader QRS
complex). In acute haemodynamic studies, however, LV
pacing has been shown to be either equal to [29] or supe-
rior to [21,39,43,44] biventricular pacing. We are not
aware of any study showing the converse. Kass et al
reported that patients with the greatest QRS prolongation
showed the greatest acute haemodynamic benefit, but
there was no relationship between QRS narrowing associ-
ated with pacing and acute haemodynamic improvement.
LV pacing was specifically superior to biventricular pacing
despite a much broader paced QRS complex. It is certainly
true that analysis of pressure–volume loops suggested that
the mechanism of benefit was an improvement in LV con-
tractile function, with no significant change in LV diastolic
compliance [21]. Varma et al, in a recent study, assessed
the impact of different pacing sites on LV coordination
using LV pressure–dimension loops in patients with CHF
and LBBB. Dyssynchrony of intraventricular conduction
results in a low ‘cycle efficiency’, yet there was no consis-
tency regarding the optimal pacing chamber or site to
improve cycle efficiency [45]. This group conversely
observed that LV pacing provided greater overall acute
haemodynamic benefit than biventricular pacing [44].
Kerwin  et al recently showed that biventricular pacing did
not improve intraventricular dyssynchrony, but did improve
interventricular dyssynchrony [46].
The mechanism(s) of acute haemodynamic benefit from
biventricular pacing is therefore not understood. Although
Kass et al did not find evidence to support it, the possibil-
ity of an improvement in diastolic filling cannot be
excluded. Right ventricular pacing clearly worsens dias-
tolic filling [14], so the converse with LV pacing is cer-
tainly possible. CHF patients with high LVEDPs have
marked diastolic ventricular interaction; that is, the filling of
the LV is constrained by the RV and by the pericardium
[47]. Our preliminary data suggests that, by permitting the
LV to fill before the RV, LV pacing may improve filling in
these patients with diastolic ventricular interaction,
whether or not they have underlying LBBB [48,49].
All of these factors serve to emphasise the need to under-
stand the effects of pacing on pathophysiology, in order to
design optimally larger clinical trials. It is unlikely, given the
non-uniform nature of the pathophysiology and the multi-
ple potential effects of pacing (reduction in presystolic
MR, recoordination of intraventricular versus interventricu-
lar contraction sequence with improvement in both con-
tractile and diastolic function), that a ‘one size fits all’
strategy is optimal. It is possible that benefit may not be
confined to patients with LBBB, nor necessarily that all
such patients will benefit. Furthermore, LV pacing may be
superior to biventricular pacing. Previous experience of a
dichotomy between symptomatic and prognostic effects
with positive inotropic agents in CHF should sound a note
of caution. Encouraging preliminary data in this regard
suggest that the improvement in myocardial contractile
performance with biventricular pacing is associated with a
fall in myocardial O2 consumption [50]. Furthermore,
whereas RV pacing increases plasma norepinephrine,
biventricular pacing is associated with a reduction [22].
We strive to practice ‘evidence based medicine’. We must,
however, remember that simply by virtue of their size, large
‘clinical trials’ will not always provide the answers for indi-
vidual patients. Unless such studies are directed by a
sound understanding of pathophysiology, of its non-unifor-
mity, and of the effects of therapy on this pathophysiology,
the wrong questions may be asked in the wrong patients.
This may lead to inappropriate therapy for some patients
and missed therapeutic opportunities for others.
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